In non-oncogene-driven metastatic NSCLC treated with PD-1/PD-L1 inhibitors, higher subcutaneous fat and skeletal muscle have been linked to better clinical outcome following PD-1/PD-L1 blockade, whereas visceral and intramuscular fat showed no consistent prognostic significance (57). This evidence concerns the gene CD274 and non-small cell lung carcinoma.